Cabaletta Bio Presents Positive Data On CABA-201 At ACR Convergence 2024

(RTTNews) – Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company, announced, on Tuesday, that it has presented updated clinical data from its ongoing RESET clinical development program at the 2024 American College of Rheumatology (ACR) Convergence in Washington, D.C

admin